- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Détention brevets de la classe C07K 14/705
Brevets de cette classe: 14405
Historique des publications depuis 10 ans
|
832
|
917
|
1150
|
1279
|
1365
|
1530
|
1485
|
1394
|
1224
|
516
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 19812 |
311 |
| The Trustees of the University of Pennsylvania | 4308 |
309 |
| The Board of Trustees of the Leland Stanford Junior University | 6365 |
201 |
| Memorial Sloan-Kettering Cancer Center | 1910 |
180 |
| Regeneron Pharmaceuticals, Inc. | 4223 |
178 |
| Board of Regents, The University of Texas System | 5751 |
161 |
| Immatics Biotechnologies GmbH | 1152 |
151 |
| Novartis AG | 10904 |
140 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2837 |
128 |
| The General Hospital Corporation | 4704 |
90 |
| City of Hope | 979 |
85 |
| Autolus Limited | 251 |
80 |
| Dana-Farber Cancer Institute, Inc. | 2553 |
76 |
| CRISPR Therapeutics AG | 361 |
74 |
| Alpine Immune Sciences, Inc. | 80 |
72 |
| Baylor College of Medicine | 939 |
71 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3360 |
67 |
| Lentigen Technology, Inc. | 100 |
66 |
| Juno Therapeutics, Inc. | 383 |
65 |
| The Johns Hopkins University | 5642 |
63 |
| Autres propriétaires | 11837 |